Inactive Instrument

Meridian Bioscience, Inc.

Equities

VIVO

US5895841014

Medical Equipment, Supplies & Distribution

Diagnostic Companies and Laboratories Engages Meridian Bioscience, Inc. to Use the Lyo-Ready 1-Step RT-qPCR Mix to Develop Screening Assays

January 27, 2020 at 09:10 pm

On January 27, 2020, Meridian Bioscience, Inc. announced that certain diagnostic companies and laboratories located in China have engaged the Company to use the Company's Lyo-Ready 1-Step RT-qPCR Mix to develop screening assays for the detection of the coronavirus, currently named 2019-nCoV (the Coronavirus"), which has and is continuing to spread throughout China and other parts of the world.

Latest news about Meridian Bioscience, Inc.

Meridian Bioscience Unveils Industry-First Lyophilized Library Prep Kit for Next-Generation Sequencing, Eliminating the Need for Cold-Chain Shipping and Storage	06-26	CI
Meridian Bioscience, Inc. Drives Democratization of Next-Generation Sequencing with Reagents Enabling Ambient Temperature Shipping and Storage of Sequencing Kits	04-10	CI
Meridian Bioscience, Inc. announced that it has received KRW 128.772575398 billion in funding	11-29	CI
Meridian Bioscience, Inc. announced that it expects to receive KRW 128.772575393 billion in funding	11-21	CI
Meridian Bioscience, Inc. announced that it has received KRW 258.225164381 billion in funding from Columbus Holding Company	27/07/23	CI
Meridian Bioscience Continues Expansion of H. Pylori Diagnostic Testing Solutions with Fda Clearance of Premier Hpsa Flex	25/07/23	CI
Meridian Bioscience, Inc. announced that it expects to receive KRW 258.225164381 billion in funding	11/06/23	CI
Meridian Bioscience, Inc. Announces FDA Clearance for Innovative Curian® Shiga Toxin Assay	19/04/23	CI
Meridian Bioscience, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2022	09/02/23	CI
SD Biosensor, SJL Partners Acquire Meridian Bioscience	31/01/23	MT
Meridian Bioscience, Inc.(NasdaqGM:VIVO) dropped from NASDAQ Composite Index	31/01/23	CI
Meridian Bioscience, Inc.(NasdaqGS:VIVO) dropped from S&P Healthcare Equipment Select Industry Index	31/01/23	CI
Meridian Bioscience, Inc.(NasdaqGS:VIVO) dropped from S&P 600	31/01/23	CI
Meridian Bioscience, Inc.(NasdaqGS:VIVO) dropped from S&P Composite 1500	31/01/23	CI
Meridian Bioscience, Inc.(NasdaqGS:VIVO) dropped from S&P Global BMI Index	31/01/23	CI
Meridian Bioscience, Inc.(NasdaqGS:VIVO) dropped from S&P TMI Index	31/01/23	CI
Meridian Bioscience, Inc.(NasdaqGS:VIVO) dropped from S&P 1000	31/01/23	CI
Meridian Bioscience, Inc.(NasdaqGS:VIVO) dropped from S&P 600 Health Care	31/01/23	CI
SD BioSensor, Inc and SJL Partners completed the acquisition of Meridian Bioscience, Inc. from Impactive Capital LP, BlackRock, Inc., The Vanguard Group, Inc, Royce & Associates, LP and others.	30/01/23	CI
DoubleVerify Holdings to Replace Meridian Bioscience in S&P SmallCap 600	26/01/23	MT
Meridian Bioscience Says Closing Date of Pending Merger With SD Biosensor, Others Pushed Back to Jan. 31	12/12/22	MT
Meridian Bioscience Fiscal Q4 Adjusted EPS, Revenue Decline	22/11/22	MT
Earnings Flash (VIVO) MERIDIAN BIOSCIENCE Reports Q4 Revenue $65.7M	22/11/22	MT
Earnings Flash (VIVO) MERIDIAN BIOSCIENCE Reports Q4 EPS $0.20	22/11/22	MT
Meridian Bioscience, Inc. Reports Earnings Results for the Full Year Ended September 30, 2022	22/11/22	CI

Chart Meridian Bioscience, Inc.

Duration

Period

More charts

Company Profile

Meridian Bioscience, Inc. is a life science company. The Company is engaged in the development, manufacture, sale and distribution of diagnostic testing systems and kits, primarily for certain gastrointestinal and respiratory infectious diseases, and elevated blood lead levels; and the manufacture and distribution of bulk antigens, antibodies, immunoassay blocking reagents, specialized polymerase chain reaction (PCR) master mixes, and bioresearch reagents used by other diagnostic test manufacturers and researchers in immunological and molecular tests for human, animal, plant and environmental applications. The Company's segments include Diagnostics and Life Science. The Diagnostics segment consists of manufacturing operations for infectious disease products in Cincinnati, Ohio; Quebec City, Canada; and Modi'in, Israel. The Life Science segment consists of manufacturing operations in Memphis, Tennessee; Boca Raton, Florida; London, England; and Luckenwalde, Germany.

Sector

Medical Equipment, Supplies & Distribution

More about the company

Sector Other Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.
ABBOTT LABORATORIES	-6.24%	180B
MEDTRONIC PLC	-6.08%	99.21B
BECTON, DICKINSON AND COMPANY	-5.98%	66.25B
DEXCOM, INC.	-9.35%	44.74B
CENCORA, INC.	+8.34%	43.82B
HOYA CORPORATION	+10.30%	41.96B
METTLER-TOLEDO INTERNATIONAL, INC.	+11.88%	28.98B
WEST PHARMACEUTICAL SERVICES, INC.	-8.38%	23.5B
TERUMO CORPORATION	+15.49%	24.07B

Other Medical Equipment, Supplies & Distribution